article thumbnail

BD announces first pharma-sponsored clinical trial using BD Libertas wearable injector technology for biologic drugs

Express Pharma

The biologics market is expected to grow to more than $670 billion(iv) by 2030, and for pharmaceutical companies developing these complex drugs, the BD Libertas Wearable Injector offers a customisable, patient-centric solution. Biologics Market Size – Industry Report on Share, Growth Trends & Forecasts Analysis (2025 – 2030).

article thumbnail

AstraZeneca announces $50bn US investment plans by 2030

Pharmaceutical Technology

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing, and research and development (R&D). It will also support our ambition to reach $80bn in revenue by 2030.” Credit: grandbrothers/Shutterstock.com. Give your business an edge with our leading industry insights.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA approves Hikma’s Tyzavan for multiple infections

Pharmaceutical Business Review

Our dedicated and specialised commercial team will drive the launch of Tyzavan, ensuring its successful introduction and adoption in US hospitals.” With a shelf life of 16 months without the need for refrigeration, Tyzavan offers practical benefits for hospital storage.

article thumbnail

Virginia drug plant will be AstraZeneca’s largest

Beckers Hospital Review

manufacturing and research by 2030, with a focus on producing drug substances for chronic disease treatments. The post Virginia drug plant will be AstraZeneca’s largest appeared first on Becker's Hospital Review | Healthcare News & Analysis. AstraZeneca is investing $50 billion in U.S.

article thumbnail

Indian pharma industry profitability improves as pricing environment eases: Equirus Capital

Express Pharma

24 mega-selling drugs with combined annual sales exceeding $250 billion will lose patent protection by 2030 and will soon be open for generic manufacturing. per cent, API Pharma at 12.6 per cent vs 7.6 per cent and Diagnostics at 13.6 per cent vs 12.6 per cent in FY23-25.

article thumbnail

India’s life sciences sector poised for transformational growth: Vishal Goel

Express Pharma

billion square feet of healthcare space by 2030 and 2.9 million hospital beds to meet global standards. This year alone, we witnessed the demand for healthcare infrastructure skyrocket, with estimates indicating a need for an additional 1.3

article thumbnail

CPHI & PMEC India expo to be held from Nov 26-28, 2024

Express Pharma

India’s pharma industry is on an impressive growth trajectory, expected to reach $65 billion by 2024 and to double to $130 billion by 2030. Renowned as a comprehensive, one-stop destination for innovative, cost-effective solutions, the expo will be showcasing the pharmaceutical industry’s modernisation, innovation, and sustainability.